Alembic Pharmaceuticals Ltd (ALEM.NS)
22 Jun 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|66||2016||Executive Chairman of the Board, Chief Executive Officer|
|54||2014||Chief Financial Officer, Director - Finance, Executive Director|
|2018||Head of Osteofit and Ouron Divisions, Senior Vice President - Finance|
|2018||Compliance Officer, Company Secretary|
|38||2016||Managing Director, Executive Director|
- BRIEF-Alembic Pharmaceuticals' Panelav Unit Gets Zero 483 Observations From U.S. FDA
- BRIEF-Alembic Pharmaceuticals Gets U.S. FDA Nod For Acyclovir Ointment USP, 5 Pct
- BRIEF-U.S. FDA Observes Alembic Pharma Failed To Review Any Unexplained Discrepancy On Inspection Of Co's Panelav Plant - CNBC TV18
- BRIEF-Alembic Pharmaceuticals Says U.S FDA Issued 3 Observations For Panelav Formulation Facility
- BRIEF-India's Alembic Pharmaceuticals Dec Qtr Consol PAT Rises